• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2015-2017 年美国医疗机构血流感染住院患者分离细菌的发生频率和药敏情况。

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017).

机构信息

JMI Laboratories, North Liberty, Iowa, USA.

JMI Laboratories, North Liberty, Iowa, USA.

出版信息

Diagn Microbiol Infect Dis. 2019 Nov;95(3):114850. doi: 10.1016/j.diagmicrobio.2019.06.002. Epub 2019 Jun 11.

DOI:10.1016/j.diagmicrobio.2019.06.002
PMID:31296360
Abstract

The frequency and antimicrobial susceptibility of organisms causing bloodstream infections in the United States were evaluated by consecutively collecting (1/patient) 9210 bacterial isolates from 33 US medical centers in 2015-2017. Isolates were susceptibility tested by reference broth microdilution methods. Whole genome sequencing was performed on carbapenem-resistant Enterobacteriaceae (CRE). The most common organisms were Staphylococcus aureus (24.3%), Escherichia coli (20.8%), and Klebsiella pneumoniae (9.1%). Overall, 50.0% of isolates were gram-negative bacilli and 41.4% were Enterobacteriaceae. The most active agents against Enterobacteriaceae were ceftazidime-avibactam (99.9% susceptible), amikacin (99.7% susceptible), and the carbapenems meropenem and doripenem (99.1% susceptible). Among 28 CRE isolates (0.7% of Enterobacteriaceae), 21 produced a KPC-like carbapenemase, 2 an NMD-like, and 1 a KPC-17 and an NDM-1. Colistin (100.0% susceptible), ceftolozane-tazobactam (98.7% susceptible), ceftazidime-avibactam (98.2% susceptible), amikacin (97.9% susceptible), and tobramycin (95.6% susceptible) were very active against Pseudomonas aeruginosa. Among S. aureus isolates, 57.8% were oxacillin-susceptible.

摘要

2015 年至 2017 年,连续从美国 33 家医疗中心的 9210 名患者中采集(1/患者)细菌分离株,评估导致血流感染的美国生物体的频率和抗菌药物敏感性。采用参考肉汤微量稀释法对分离株进行药敏试验。对耐碳青霉烯类肠杆菌科(CRE)进行全基因组测序。最常见的生物体是金黄色葡萄球菌(24.3%)、大肠杆菌(20.8%)和肺炎克雷伯菌(9.1%)。总体而言,50.0%的分离株为革兰氏阴性杆菌,41.4%为肠杆菌科。对肠杆菌科最有效的药物是头孢他啶-阿维巴坦(99.9%敏感)、阿米卡星(99.7%敏感)和碳青霉烯类美罗培南和多尼培南(99.1%敏感)。在 28 株 CRE 分离株(肠杆菌科的 0.7%)中,21 株产生了类似于 KPC 的碳青霉烯酶,2 株产生了类似于 NMD 的酶,1 株产生了 KPC-17 和 NDM-1。多粘菌素(100.0%敏感)、头孢洛扎-他唑巴坦(98.7%敏感)、头孢他啶-阿维巴坦(98.2%敏感)、阿米卡星(97.9%敏感)和妥布霉素(95.6%敏感)对铜绿假单胞菌非常有效。在金黄色葡萄球菌分离株中,57.8%对苯唑西林敏感。

相似文献

1
Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017).2015-2017 年美国医疗机构血流感染住院患者分离细菌的发生频率和药敏情况。
Diagn Microbiol Infect Dis. 2019 Nov;95(3):114850. doi: 10.1016/j.diagmicrobio.2019.06.002. Epub 2019 Jun 11.
2
Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.2011年至2015年在美国医疗中心住院治疗肺炎的患者中分离出的革兰氏阴性菌对头孢他啶-阿维巴坦的抗菌活性
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02083-16. Print 2017 Apr.
3
Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).头孢他啶-阿维巴坦的抗菌活性和谱在测试儿科患者的革兰氏阴性菌时的结果:来自 INFORM 监测计划(美国,2011-2015 年)。
Pediatr Infect Dis J. 2018 Jun;37(6):549-554. doi: 10.1097/INF.0000000000001859.
4
Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.头孢洛扎/他唑巴坦与头孢他啶/阿维巴坦对大肠埃希菌、肺炎克雷伯菌和铜绿假单胞菌多重耐药菌株抗菌活性的比较。
Int J Infect Dis. 2017 Sep;62:39-43. doi: 10.1016/j.ijid.2017.06.007. Epub 2017 Jun 10.
5
Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).比较头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对 2017-2018 年美国医疗中心住院肺炎患者分离的革兰氏阴性菌的体外活性。
Diagn Microbiol Infect Dis. 2020 Mar;96(3):114833. doi: 10.1016/j.diagmicrobio.2019.05.005. Epub 2019 May 10.
6
Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.美国最佳耐药性监测计划国际网络四年(2012年至2015年)期间铜绿假单胞菌的抗菌药敏结果
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02252-16. Print 2017 Mar.
7
Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).美国医疗中心 ICU 住院肺炎患者分离的革兰氏阴性菌的频率和抗菌药物敏感性(2015-17 年)。
J Antimicrob Chemother. 2018 Nov 1;73(11):3053-3059. doi: 10.1093/jac/dky279.
8
[Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].[2011年、2013年和2016年医院获得性菌血症病原菌的微生物学特征]
Sheng Wu Gong Cheng Xue Bao. 2018 Aug 25;34(8):1205-1217. doi: 10.13345/j.cjb.180192.
9
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.作为监测项目“头孢洛扎-他唑巴坦敏感性评估项目”的一部分,对2013年至2016年在美国医院分离出的具有各种耐药模式的肠杆菌科细菌和铜绿假单胞菌进行头孢洛扎-他唑巴坦抗菌活性测试
Microb Drug Resist. 2018 Jun;24(5):563-577. doi: 10.1089/mdr.2017.0266. Epub 2017 Oct 17.
10
Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.2012 - 2014年美国医院腹腔内感染分离出的需氧革兰阴性菌对头孢他啶 - 阿维巴坦的敏感性
Surg Infect (Larchmt). 2016 Aug;17(4):473-8. doi: 10.1089/sur.2016.036. Epub 2016 Apr 22.

引用本文的文献

1
Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.革兰氏阴性菌对头孢他啶-阿维巴坦耐药性的全球趋势:系统评价与荟萃分析
Antimicrob Resist Infect Control. 2025 Feb 11;14(1):10. doi: 10.1186/s13756-025-01518-5.
2
Prevalence of colistin resistance in clinical isolates of : a systematic review and meta-analysis.临床分离株中黏菌素耐药性的流行情况:一项系统评价和荟萃分析。
Front Microbiol. 2024 Oct 9;15:1477836. doi: 10.3389/fmicb.2024.1477836. eCollection 2024.
3
Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective.
多药耐药性对铜绿假单胞菌毒力和适应性的影响:微生物学和临床视角。
Infection. 2024 Aug;52(4):1235-1268. doi: 10.1007/s15010-024-02313-x. Epub 2024 Jul 2.
4
Characterization of Carbapenemase- and ESBL-Producing Gram-Negative Bacilli Isolated from Patients with Urinary Tract and Bloodstream Infections.从尿路感染和血流感染患者中分离出的产碳青霉烯酶和超广谱β-内酰胺酶革兰氏阴性杆菌的特征分析
Antibiotics (Basel). 2023 Aug 30;12(9):1386. doi: 10.3390/antibiotics12091386.
5
Multicenter Surveillance of Antimicrobial Resistance among Gram-Negative Bacteria Isolated from Bloodstream Infections in Ghana.加纳血流感染分离出的革兰氏阴性菌抗菌药物耐药性的多中心监测
Antibiotics (Basel). 2023 Jan 27;12(2):255. doi: 10.3390/antibiotics12020255.
6
Changes in Antimicrobial Resistance and Etiology of Blood Culture Isolates: Results of a Decade (2010-2019) of Surveillance in a Northern Region of Colombia.血培养分离株的抗菌药物耐药性和病原学变化:哥伦比亚北部地区十年(2010 - 2019年)监测结果
Infect Drug Resist. 2022 Oct 20;15:6067-6079. doi: 10.2147/IDR.S375206. eCollection 2022.
7
Trends of Bloodstream Infections in a University Hospital During 12 Years.12 年间某大学医院血流感染的趋势。
Pol J Microbiol. 2022 Sep 24;71(3):443-452. doi: 10.33073/pjm-2022-039. eCollection 2022 Sep 1.
8
Drug susceptibility and molecular epidemiology of in bloodstream infections in Shanxi, China.中国山西血流感染的药物敏感性及分子流行病学研究
PeerJ. 2021 Oct 25;9:e12371. doi: 10.7717/peerj.12371. eCollection 2021.
9
Ceftazidime-avibactam: are we safe from class A carbapenemase producers' infections?头孢他啶-阿维巴坦:我们能免受 A 类碳青霉烯酶产生菌感染吗?
Folia Microbiol (Praha). 2021 Dec;66(6):879-896. doi: 10.1007/s12223-021-00918-5. Epub 2021 Sep 9.
10
Clinical characteristics, appropriateness of empiric antibiotic therapy, and outcome of Pseudomonas aeruginosa bacteremia across multiple community hospitals.跨多家社区医院的铜绿假单胞菌菌血症的临床特征、经验性抗生素治疗的适宜性和结局。
Eur J Clin Microbiol Infect Dis. 2022 Jan;41(1):53-62. doi: 10.1007/s10096-021-04342-y. Epub 2021 Aug 30.